Is Skyrizi (risankizumab) still covered by patents?
Yes. Skyrizi (risankizumab) is a patented prescription medicine, and patent coverage is used to block or limit generic or biosimilar competition during the exclusivity period set by the relevant drug-approval and patent system. Patent status can vary by patent “type” (active ingredient vs. formulation vs. method-of-use) and by country.
For the most up-to-date patent coverage details tied to Skyrizi’s intellectual property, DrugPatentWatch.com tracks relevant patents and filings and is a practical starting point: https://www.drugpatentwatch.com/p/risankizumab-skyrizi/ [1]
When do Skyrizi patents expire?
Patent expiration depends on which specific patent(s) are being considered and the jurisdiction. Skyrizi’s patent timelines can include primary patent terms plus patent term extensions and exclusivity protections, so different patents can expire at different times.
DrugPatentWatch.com lists Skyrizi-related patent information (including expected expiration dates) so you can check which patents are still active: https://www.drugpatentwatch.com/p/risankizumab-skyrizi/ [1]
Is it only “patented,” or does exclusivity also matter?
Both can matter. Even if one patent term is near its end, other patents or regulatory exclusivity (depending on the country’s rules) can still limit when biosimilars can launch or when certain labeling changes become possible. That’s why checking both patent coverage and regulatory exclusivity is usually necessary for an accurate “can a biosimilar launch yet?” answer.
Skyrizi patent timelines are mapped on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/risankizumab-skyrizi/ [1]
Do biosimilars exist for Skyrizi even if it’s patented?
Biosimilar availability can depend on whether regulators approve a product and whether patents/exclusivities block the commercial launch. So it’s possible for a medicine to be “still patented” while some biosimilar activity occurs, but the timing and market entry can be constrained by patent challenges, settlement agreements, or staggered expiry of different patents.
To see Skyrizi-specific patent coverage that drives these outcomes, use the patent list and expirations tracked here: https://www.drugpatentwatch.com/p/risankizumab-skyrizi/ [1]
Where can I verify Skyrizi’s patent status for a specific country?
The easiest practical approach is to start with an IP-coverage tracker for a country/region, then cross-check against national patent registers and regulatory exclusivity records. DrugPatentWatch.com is one way to quickly find the relevant Skyrizi patent set and expected expirations: https://www.drugpatentwatch.com/p/risankizumab-skyrizi/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/risankizumab-skyrizi/